Plecanatide: complete guide

Plecanatide is a 16-amino-acid uroguanylin analog approved for two constipation disorders in adults. This guide covers its structure, mechanism, trials and warnings.

Complete guide5 min read

Key takeaway

FDA approved plecanatide as Trulance on January 19, 2017. It is a 16-amino-acid analog of human uroguanylin with two disulfide bonds. In its phase 3 chronic constipation trial of 1,394 adults, 19.5% to 21.0% of plecanatide patients were durable responders, versus 10.2% on placebo.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA approved Trulance on January 19, 2017.” (this article)
ClassGut & digestion
Body systemsGut
Studies cited2 in this article · 2 across 1 article on Plecanatide
Related productsResearch peptide catalog

Plecanatide is a 16-amino-acid peptide built to mimic uroguanylin, a hormone the gut makes on its own. It acts on the same receptor as linaclotide and treats two constipation disorders in adults. This guide covers its structure, mechanism, FDA-labeled uses, pivotal trials and boxed warning, with sources checked on November 17, 2026.

Quick answer: Plecanatide is a prescription guanylate cyclase-C agonist for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It carries a boxed warning on serious dehydration in children. Diarrhea is the most common side effect on its label.

Vitrapep does not sell plecanatide; this page is a reference summary of published research and regulatory information.

What is plecanatide?

Plecanatide is a guanylate cyclase-C agonist peptide. The Trulance label calls it “a 16 amino acid peptide” and “a structural analog of human uroguanylin” (Trulance label, 2024). The NCI Thesaurus, quoted in PubChem, calls it “almost structurally identical to human uroguanylin.”

It counts as a peptide because it is a short chain of amino acids. Two disulfide bonds, between cysteines 4 and 12 and between 7 and 15, fold the chain into loops. That pairing appears in its chemical name on the label. PubChem lists the formula as C65H104N18O26S4 and the molecular weight as 1,681.9 g/mol (PubChem CID 70693500). Our peptide primer explains how such chains are classed.

Drugs@FDA lists the original approval of Trulance (NDA 208745) on January 19, 2017. Salix is the applicant (Drugs@FDA).

Table 1

Plecanatide: key facts

Fact Detail
Structure type 16-amino-acid peptide with two disulfide bonds; uroguanylin analog
Class Guanylate cyclase-C agonist
Molecular formula C65H104N18O26S4
Molecular weight 1,681.9 g/mol
First FDA approval January 19, 2017 (Trulance, NDA 208745)
Brand names (US) Trulance

How does plecanatide work?

Plecanatide acts on guanylate cyclase-C (GC-C), a receptor on the cells lining the intestine. LiverTox text in PubChem describes it as a “minimally absorbed agonist of guanylate cyclase C receptors in the intestine.” So it acts within the gut.

The Trulance label explains the chain of events. GC-C activation causes “an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP).” Inside the cell, cGMP stimulates chloride and bicarbonate secretion, mainly through “the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel.”

The label also cites animal work: “In an animal model of visceral pain, plecanatide reduced abdominal muscle contractions.” That is animal evidence. Linaclotide shares this mechanism; see our linaclotide guide.

What is plecanatide approved for?

The Trulance label lists two indications, both in adults:

  • “chronic idiopathic constipation (CIC)”; and
  • “irritable bowel syndrome with constipation (IBS-C).”

The label states that its safety and effectiveness “have not been established in patients less than 18 years of age.”

What did the key trials show?

Chronic idiopathic constipation. This phase III, randomized, double-blind, placebo-controlled trial randomized 1,394 adults. The primary end point was the share of durable overall responders for complete spontaneous bowel movements over 12 weeks. Responders were 19.5% to 21.0% across the plecanatide groups, versus 10.2% on placebo (P < 0.001 for both) (Miner et al., 2017; NCT01982240).

IBS with constipation. Two identical phase 3 trials randomized 2,189 adults in total. An overall responder had at least 30% less worst abdominal pain plus more complete bowel movements. Both had to happen in the same week, for at least 6 of 12 weeks. In Study 1, 29.5% to 30.2% responded on plecanatide versus 17.8% on placebo (P < 0.001). In Study 2, the figures were 21.5% to 24.0% versus 14.2% (P = 0.009 and P < 0.001) (Brenner et al., 2018).

The two IBS-C trials are registered as NCT02387359 and NCT02493452. All of these trials were in humans.

What side effects does the label list?

Trulance carries a boxed warning: “Risk of serious dehydration in pediatric patients.” The label states that Trulance is contraindicated in patients under 6. It also says to avoid use in patients 6 to under 18. The warning rests on nonclinical studies in which young mice died of dehydration. Those are animal data.

The label’s two warnings cover that dehydration risk and diarrhea. Its highlights state: “Most common adverse reaction (≥2%) is diarrhea.”

What is plecanatide’s regulatory status, and how is it used in research?

Plecanatide is a prescription drug. Drugs@FDA lists Trulance as a current prescription product from Salix. DailyMed lists one Trulance label, revised in March 2024.

The research summarized here is human clinical trials, plus animal studies cited in the label. ClinicalTrials.gov also lists a completed phase 2 trial in children 6 to under 18 with IBS-C, registered as NCT03596905. The current label still does not establish pediatric use.

Frequently asked questions about plecanatide

Is plecanatide a peptide?

Yes. It is a 16-amino-acid peptide with two disulfide bonds, modeled on human uroguanylin.

What is the difference between plecanatide and linaclotide?

Both activate GC-C in the gut. Plecanatide has 16 amino acids and two disulfide bonds. Linaclotide has 14 amino acids and three. Their labels also differ on pediatric use.

When was plecanatide approved?

FDA approved Trulance on January 19, 2017.

Why does plecanatide have a boxed warning?

In young mice, it caused deaths from dehydration. The label contraindicates it under age 6 and says to avoid it from 6 to under 18.

What is the most common side effect?

Diarrhea, per the label’s highlights.

What to know now

  • Structure: 16-amino-acid uroguanylin analog; two disulfide bonds; 1,681.9 g/mol.
  • Mechanism: GC-C agonist; raises cGMP; chloride and bicarbonate secretion via CFTR.
  • Approval: Trulance, January 19, 2017; adults with CIC or IBS-C.
  • Evidence: 19.5% to 21.0% vs 10.2% durable responders in the CIC trial of 1,394 adults.
  • Safety: boxed warning on pediatric dehydration; diarrhea most common.

What we’re watching

Whether results from the completed pediatric IBS-C trial (NCT03596905) lead to a Trulance label change. Further label revisions on DailyMed. Related guides: linaclotide and teduglutide.

More for gut

All 11 compounds for gut

Sources: Salix Pharmaceuticals 2024, TRULANCE (plecanatide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 208745 (TRULANCE) . Retrieved November 17, Drugs@FDA: NDA 208745 (TRULANCE); National Center for Biotechnology Information 2026, PubChem compound summary for CID 70693500, plecanatide; Miner 2017, The American Journal of Gastroenterology, 112; Bausch Health Americas 2013, 12-week study of plecanatide for CIC (the CIC3 study); Brenner 2018, The American Journal of Gastroenterology, 113; Bausch Health Americas 2015; Bausch Health Americas 2015, Second plecanatide study in irritable bowel syndrome with constipation (IBS-C); Bausch Health Americas 2018. All 9 citations

Back to the research library

References

  1. Salix Pharmaceuticals, Inc. (2024). TRULANCE (plecanatide) prescribing information (revised 3/2024). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe2895bf-71a6-493a-b0ca-e06b2dfefc82
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 208745 (TRULANCE). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208745
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 70693500, plecanatide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/70693500
  4. Miner, P. B., Jr., et al. (2017). A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. The American Journal of Gastroenterology, 112(4), 613–621. https://doi.org/10.1038/ajg.2016.611
  5. Bausch Health Americas, Inc. (2013). 12-week study of plecanatide for CIC (the CIC3 study) (ClinicalTrials.gov ID NCT01982240). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01982240
  6. Brenner, D. M., et al. (2018). Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: Results of two phase 3 randomized clinical trials. The American Journal of Gastroenterology, 113(5), 735–745. https://doi.org/10.1038/s41395-018-0026-7
  7. Bausch Health Americas, Inc. (2015). The plecanatide irritable bowel syndrome with constipation safety and efficacy study (IBS-C) (ClinicalTrials.gov ID NCT02387359). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02387359
  8. Bausch Health Americas, Inc. (2015). Second plecanatide study in irritable bowel syndrome with constipation (IBS-C) (ClinicalTrials.gov ID NCT02493452). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02493452
  9. Bausch Health Americas, Inc. (2018). Efficacy and safety of plecanatide in children 6 to <18 years with irritable bowel syndrome with constipation (IBS-C) (ClinicalTrials.gov ID NCT03596905). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03596905